LONDON, ENGLAND, 28 November, 2006 - SkyePharma PLC (LSE: SKP; NASDAQ: SKYE)
today announces that Solaraze(R), its topical 3% gel (diclofenac sodium)
treatment for actinic keratosis, has been approved for registration by the
Australian Government Department of Health and Ageing Therapeutic Goods
Administration (TGA).
